1. ZHAW digitalcollection
  2. School of Management and Law
  3. Publikationen
  4. Publikationen School of Management and Law
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChen, Wenjia-
dc.contributor.authorWang, Yi-
dc.contributor.authorZemlyanska, Yaroslava-
dc.contributor.authorButani, Dimple-
dc.contributor.authorWong, Nigel Chong Boon-
dc.contributor.authorVirabhak, Suchin-
dc.contributor.authorMatchar, David Bruce-
dc.contributor.authorTeerawattananon, Yot-
dc.date.accessioned2023-12-01T16:13:58Z-
dc.date.available2023-12-01T16:13:58Z-
dc.date.issued2023-09-
dc.identifier.issn1098-3015de_CH
dc.identifier.issn1524-4733de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/29261-
dc.description.abstractObjectives: This study aimed to perform a comprehensive review of modeling approaches and methodological and policy challenges in the economic evaluation (EE) of precision medicine (PM) across clinical stages. Methods: First, a systematic review was performed to assess the approaches of EEs in the past 10 years. Next, a targeted review of methodological articles was conducted for methodological and policy challenges in performing EEs of PM. All findings were synthesized into a structured framework that focused on patient population, Intervention, Comparator, Outcome, Time, Equity and ethics, Adaptability and Modeling aspects, named the “PICOTEAM” framework. Finally, a stakeholder consultation was conducted to understand the major determinants of decision making in PM investment. Results: In 39 methodological articles, we identified major challenges to the EE of PM. These challenges include that PM applications involve complex and evolving clinical decision space, that clinical evidence is sparse because of small subgroups and complex pathways in PM settings, a one-time PM application may have lifetime or intergenerational impacts but long-term evidence is often unavailable, and that equity and ethics concerns are exceptional. In 275 EEs of PM, current approaches did not sufficiently capture the value of PM compared with targeted therapies, nor did they differentiate Early EEs from Conventional EEs. Finally, policy makers perceived the budget impact, cost savings, and cost-effectiveness of PM as the most important determinants in decision making. Conclusions: There is an urgent need to modify existing guidelines or develop a new reference case that fits into the new healthcare paradigm of PM to guide decision making in research and development and market access.de_CH
dc.language.isoende_CH
dc.publisherElsevierde_CH
dc.relation.ispartofValue in healthde_CH
dc.rightsLicence according to publishing contractde_CH
dc.subjectCost effectivenessde_CH
dc.subjectEarly health technology assessmentde_CH
dc.subjectEconomic evaluationde_CH
dc.subjectGene therapyde_CH
dc.subject.ddc362.1041: Gesundheitsökonomiede_CH
dc.titleEvaluating the value for money of precision medicine from early cycle to market access : a comprehensive review of approaches and challengesde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementSchool of Management and Lawde_CH
zhaw.organisationalunitWinterthurer Institut für Gesundheitsökonomie (WIG)de_CH
dc.identifier.doi10.1016/j.jval.2023.05.001de_CH
dc.identifier.pmid37187236de_CH
zhaw.funding.euNode_CH
zhaw.issue9de_CH
zhaw.originated.zhawNode_CH
zhaw.pages.end1434de_CH
zhaw.pages.start1425de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume26de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen School of Management and Law

Files in This Item:
There are no files associated with this item.
Show simple item record
Chen, W., Wang, Y., Zemlyanska, Y., Butani, D., Wong, N. C. B., Virabhak, S., Matchar, D. B., & Teerawattananon, Y. (2023). Evaluating the value for money of precision medicine from early cycle to market access : a comprehensive review of approaches and challenges. Value in Health, 26(9), 1425–1434. https://doi.org/10.1016/j.jval.2023.05.001
Chen, W. et al. (2023) ‘Evaluating the value for money of precision medicine from early cycle to market access : a comprehensive review of approaches and challenges’, Value in health, 26(9), pp. 1425–1434. Available at: https://doi.org/10.1016/j.jval.2023.05.001.
W. Chen et al., “Evaluating the value for money of precision medicine from early cycle to market access : a comprehensive review of approaches and challenges,” Value in health, vol. 26, no. 9, pp. 1425–1434, Sep. 2023, doi: 10.1016/j.jval.2023.05.001.
CHEN, Wenjia, Yi WANG, Yaroslava ZEMLYANSKA, Dimple BUTANI, Nigel Chong Boon WONG, Suchin VIRABHAK, David Bruce MATCHAR und Yot TEERAWATTANANON, 2023. Evaluating the value for money of precision medicine from early cycle to market access : a comprehensive review of approaches and challenges. Value in health. September 2023. Bd. 26, Nr. 9, S. 1425–1434. DOI 10.1016/j.jval.2023.05.001
Chen, Wenjia, Yi Wang, Yaroslava Zemlyanska, Dimple Butani, Nigel Chong Boon Wong, Suchin Virabhak, David Bruce Matchar, and Yot Teerawattananon. 2023. “Evaluating the Value for Money of Precision Medicine from Early Cycle to Market Access : A Comprehensive Review of Approaches and Challenges.” Value in Health 26 (9): 1425–34. https://doi.org/10.1016/j.jval.2023.05.001.
Chen, Wenjia, et al. “Evaluating the Value for Money of Precision Medicine from Early Cycle to Market Access : A Comprehensive Review of Approaches and Challenges.” Value in Health, vol. 26, no. 9, Sept. 2023, pp. 1425–34, https://doi.org/10.1016/j.jval.2023.05.001.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.